Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NordiNet International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin

Trial Profile

NordiNet International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatropin (Primary)
  • Indications Dwarfism; Growth disorders; Noonan syndrome; Short stature; Somatotropin deficiency; Turner's syndrome
  • Focus Therapeutic Use
  • Acronyms NordiNet IOS
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 22 Mar 2023 Results of secondary analysis from NCT00960128 and NCT01009905 assessing the effectiveness and safety of Norditropin (somatropin, Novo Nordisk) with up to 10 years of follow-up in children with TS published in the Journal of Clinical Endocrinology and Metabolism
    • 23 Mar 2021 Results assessing effectiveness and Safety of Early Growth Hormone Treatment in Children Born Small for Gestational Age from NordiNet IOS (NCT00960128) and ANSWER (NCT01009905) programs presented at the 103rd Annual Meeting of the Endocrine Society
    • 05 Aug 2017 Results (n=172) assessing long term efficacy and safety published in the European Journal of Endocrinology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top